Advanced drug delivery systems (ADDS) development and manufacturing

Debio R.P. is a pharmaceutical research, development and production facility inspected by the American Food and Drug Administration (FDA) and SwissMedic.

The Company, a world leader in polylactic-co-glycolic acid (PLGA)-based injectable, sustained-release technology, achieved prominence in 1986 with the launch of the drug Decapeptyl®, a novel injectable controlled-release formulation of triptorelin - a Luteinizing Hormone-Releasing Hormone agonist (LHRHa). This mode of  administration developed by Debio R.P. relies on the active substance being "wrapped" in a PLGA polymer to allow gradual dissolution and distribution of the substance in the patient's body.

Milestones

The Company has succeeded in producing formulations allowing monthly or 3-monthly injections and has successfully completed phase III clinical studies with a 6 month formulation. It is also focusing on nanoparticular drug delivery systems.

Management

Bertrand Ducrey Chief Executive Officer, Debio R.P. S. A

Dr. Ducrey received his Diploma of Pharmacy from the School of Pharmacy of Lausanne University, Switzerland in 1990 and then obtained his Ph.D. in Pharmaceutical Sciences in 1995. He joined Debio R.P. in 1995 as Pharmaceutical Project Manager. He spent two years at Debiopharm S.A. as Innovative Formulation Manager. In 2004, he returned to Debio R.P. S.A. to head the company as Chief Executive Officer.